rna
interfer
rnai
initi
recogn
natur
antivir
mechan
plant
rapidli
emerg
invalu
tool
suppress
gene
express
sequencespecif
manner
organ
includ
mammal
potenti
inhibit
replic
varieti
virus
demonstr
vitro
vivo
mous
monkey
model
result
gener
profound
interest
use
technolog
potenti
treatment
strategi
viral
infect
vaccin
drug
unavail
inadequ
review
discuss
progress
made
within
past
year
toward
har
potenti
rnai
clinic
applic
viral
infect
hurdl
yet
overcom
convent
special
cell
immun
system
secret
product
thought
involv
protect
bodi
foreign
invad
virus
howev
recent
year
new
type
genom
immun
mediat
rna
interfer
rnai
emerg
spark
intens
interest
potenti
treatment
strategi
varieti
diseas
includ
viral
infect
cancer
degen
diseas
rnai
first
recogn
natur
occur
antivir
defens
mechan
plant
rnai
long
doublestrand
ds
rna
gener
viral
infect
cleav
enzym
term
dicer
short
nucleotid
nt
dsrna
molecul
term
small
interf
si
rna
mediat
sequencespecif
gene
silenc
sirna
associ
protein
complex
call
rnainduc
silenc
complex
risc
figur
follow
sens
strand
cleav
enzym
argonaut
antisens
strand
guid
risc
correspond
messeng
rna
sequenc
homolog
nucleas
cut
mrna
result
specif
gene
silenc
context
rna
virus
sirna
design
degrad
viral
mrna
also
neg
sens
viral
genom
rna
complimentari
rna
serv
templat
new
genom
rna
synthesi
although
rnai
natur
phenomenon
plant
worm
long
dsrna
induc
interferon
respons
mammalian
cell
result
nonspecif
global
suppress
protein
synthesi
cell
death
landmark
develop
field
occur
discoveri
introduct
synthet
rna
resembl
dicerprocess
sirna
mammalian
cell
induc
sequencespecif
gene
silenc
without
evok
interferon
respons
sinc
rnai
wide
use
quick
reversegenet
approach
genefunct
analysi
ablat
specif
gene
therapeut
purpos
exquisit
sequenc
specif
high
potenc
rnai
make
attract
genesilenc
approach
rnai
found
effect
molar
basi
antisens
oligonucleotid
probabl
owe
autocatalyt
effect
rnai
wherebi
singl
sirna
molecul
reus
cleav
mani
target
mrna
molecul
rnai
induc
introduct
synthet
sirna
intracellular
gener
vectordriven
express
precursor
short
hairpin
sh
rna
box
optim
design
sirna
shrna
requir
potent
induct
rnai
box
although
rnai
integr
compon
innat
immun
respons
virus
plant
whether
true
mammal
unclear
howev
recent
describ
virusencod
counterdefens
strategi
suppressor
rnai
microrna
suggest
longstand
interact
virus
rnai
machineri
box
given
natur
antivir
role
rnai
plant
induct
mammal
introduc
sirna
phenomenon
gener
great
enthusiasm
potenti
antivir
treatment
strategi
sever
virus
wide
differ
replic
cycl
inhibit
vitro
target
viral
cellular
gene
involv
viral
life
cycl
figur
includ
positivestrand
rna
virus
includ
polio
west
nile
dengu
foot
mouth
diseas
fmd
virus
negativestrand
rna
virus
includ
respiratori
syncyti
viru
rsv
influenza
viru
doublestrand
rna
rotaviru
hiv
lentiviru
dna
virus
polyoma
viru
papilloma
viru
herp
simplex
viru
hsv
howev
replic
characterist
certain
virus
protect
rnai
exampl
although
sirna
inhibit
progeni
viru
product
genom
rna
rsv
hepat
delta
viru
rotaviru
resist
rnai
owe
tight
figur
rna
interfer
rna
interfer
initi
cell
introduct
synthet
doubl
strand
sirna
plasmid
viral
vector
encod
shrna
shrna
transcrib
nucleu
export
cytoplasm
process
sirna
dicer
possibl
anoth
ribonucleas
cytoplasm
sirna
associ
risc
complex
consist
sever
protein
human
cell
includ
dicer
argonaut
transactiv
respons
rnabind
protein
trbp
protein
activ
protein
kinas
r
pact
possibl
protein
unidentifi
date
sens
passeng
strand
sirna
cleav
within
activ
risc
passeng
strand
also
remov
albeit
slower
rate
cleavageindepend
bypass
mechan
use
microrna
process
exact
sequenc
molecular
interact
involv
risc
activ
unknown
process
shown
dot
box
sirna
guid
strand
shown
curv
indic
direct
load
risc
antisens
guid
strand
associ
matur
risc
guid
complex
correspond
mrna
sequenc
homolog
nucleas
cut
target
mrna
posit
correspond
nt
end
antisens
guid
strand
cleav
mrna
rapidli
degrad
result
gene
silenc
rnai
induc
synthet
sirna
vectordriven
express
shrna
second
method
sirna
sequenc
follow
loop
revers
complement
sirna
sequenc
clone
dna
viral
vector
express
endogen
shrna
process
cytoplasm
sirna
wherea
synthet
sirna
introduc
cell
transfect
shrna
introduc
transfect
dna
vector
transduct
viral
vector
nonrepl
recombin
viral
vector
commonli
use
shrna
express
eas
deliveri
particularli
difficulttotransfect
primari
cell
adenovirus
adenoassoci
virus
use
vector
lentivir
vector
gener
prefer
infect
activ
divid
rest
differenti
cell
stem
cell
macrophag
neuron
viral
dna
incorpor
host
genom
main
advantag
method
longterm
express
shrna
gene
silenc
fact
knockdown
persist
least
six
month
mous
brain
follow
transduct
shrnaexpress
vector
although
viral
vector
deliv
shrna
effici
sever
disadvantag
includ
vectorinduc
immun
respons
possibl
toxic
effect
longterm
rnai
induct
moreov
retrovir
integr
host
genom
also
enhanc
risk
insert
mutagenesi
exemplifi
develop
leukemia
patient
undergo
retroviralbas
gene
therapi
sever
combin
immunodefici
contrast
synthet
sirna
similarli
drug
treatment
provid
way
achiev
transient
gene
silenc
without
risk
insert
mutagenesi
immun
respons
induct
toxic
effect
longterm
rnai
induct
major
challeng
deliveri
cell
vivo
also
sirna
becom
dilut
cell
divis
silenc
effect
gener
fade
day
divid
cell
howev
nondivid
cell
macrophag
neuron
sirna
silenc
observ
least
week
thu
wherea
sirna
seem
ideal
situat
acut
viral
infect
shrna
could
use
treat
chronic
viral
infect
cancer
shrna
might
also
use
gener
cell
resist
infect
transduc
stem
cell
shrnaencod
vector
review
trend
immunolog
vol
juli
shield
protein
sequestr
membran
compart
despit
success
vitro
mani
hurdl
need
overcom
use
rnai
counteract
viru
infect
vivo
one
major
bottleneck
deliveri
sirna
shrna
appropri
cell
type
vivo
signific
progress
made
past
year
anoth
limit
lack
appropri
anim
model
mani
human
virus
nevertheless
studi
mice
prove
invalu
test
vivo
efficaci
virus
data
obtain
initi
investig
provid
glimps
success
challeng
expect
clinic
set
specif
virus
term
rnai
design
deliveri
next
subsect
describ
viral
diseas
substanti
progress
made
move
rnai
toward
therapi
although
mice
suscept
hepat
virus
transfect
plasmid
contain
viral
genom
recapitul
mani
step
viral
life
cycl
includ
dna
replic
express
core
surfac
antigen
one
first
demonstr
rnai
effect
vivo
mccaffrey
et
al
inject
plasmid
encod
hepat
b
viru
hbv
genom
alon
plasmid
encod
antihbv
shrna
hydrodynam
intraven
inject
dna
rapidli
inject
intraven
second
larg
volum
ml
result
substanti
knockdown
hbv
transcript
liver
also
result
reduct
serum
hepat
b
surfac
antigen
hbsag
level
viral
core
antigen
express
liver
cell
hydrodynam
inject
feasibl
human
entail
inject
almost
whole
blood
volum
howev
morrissey
et
al
show
regular
lowvolum
intraven
inject
chemic
modifi
sirna
contain
phosphorothio
backbon
omethyl
substitut
render
sirna
nucleaseresist
also
significantli
reduc
serum
dna
hbsag
level
mice
chemic
modifi
sirna
also
encapsul
lipid
nanoparticl
intraven
deliveri
result
extend
serum
halflif
sirna
min
h
reduc
sirna
amount
requir
compar
reduct
viral
dna
serum
hbsag
box
recent
advanc
sirna
shrna
design
recent
design
sirna
base
select
uniqu
sequenc
g
c
content
immedi
follow
nucleotid
aa
na
n
repres
nucleotid
within
target
gene
incorpor
phosphat
overhang
chanc
make
success
hit
essenti
trialanderror
process
requir
test
multipl
target
site
gene
howev
base
analys
biochem
properti
larg
number
highli
effect
sirna
morestring
algorithm
develop
predict
function
sirna
thermodynam
stabil
end
antisens
strand
emerg
crucial
criterion
sirna
effect
low
intern
stabil
end
enabl
proper
direct
load
sirna
ensur
stabl
incorpor
antisens
instead
ineffect
sens
strand
risc
increas
potenc
sirna
almost
reduc
amount
sirna
need
silenc
also
minim
offtarget
silenc
lower
thermost
also
ensur
incorpor
mismatch
sens
strand
nucleotid
complementari
posit
end
antisens
strand
antisens
strand
still
unalt
sequenc
target
specif
compromis
altern
guanosin
replac
inosin
first
posit
give
c
base
pair
similar
energi
u
base
pair
increas
propens
end
fray
low
thermodynam
stabil
mrna
cleavag
region
also
import
promot
releas
riscantisens
complex
multipl
round
activ
use
nt
sirna
instead
convent
sirna
increas
potenc
without
induc
interferon
respons
could
longer
sirna
process
dicer
gener
optim
sirna
endogen
pol
iii
promot
trna
commonli
use
drive
shrna
express
provid
effici
mechan
gener
small
rna
transcript
howev
recent
shown
insert
shrna
sequenc
backbon
mirna
eg
stem
increas
shrna
potenc
enorm
even
level
singlecopi
integr
pol
ii
cytomegaloviru
cmv
promot
use
drive
longer
shrna
system
also
enabl
multicistron
express
multipl
shrna
rnai
use
natur
antivir
defens
mechan
plant
plant
virus
also
develop
mechan
evad
rnai
although
unknown
whether
rnai
induc
natur
viral
infect
mammal
recent
studi
suggest
mammalian
virus
also
suppress
rnai
nodamura
viru
encod
protein
call
interfer
dicer
function
incorpor
sirna
risc
similarli
protein
vaccinia
viru
nonstructur
protein
influenza
viru
suppress
rnai
sequest
dsrna
nonstructur
protein
nss
la
cross
bunyaviru
tat
protein
also
suppress
rnai
addit
sirna
anoth
class
small
rna
call
mirna
also
use
rnai
pathway
contrast
sirna
mirna
cellular
gene
product
regul
endogen
gene
express
plant
worm
mammal
fact
alter
develop
b
lymphocyt
note
specif
mirnaknockout
hematopoiet
stem
cell
dicerknockout
mice
recent
virus
also
found
encod
mirna
manipul
host
mirna
epsteinbarr
viru
encod
mirna
predict
target
sever
cellular
gene
similarli
human
cytomegaloviru
encod
least
five
mirna
kaposi
sarcomaassoci
herpesviru
express
mirna
target
host
gene
exact
function
viral
mirna
yet
elucid
howev
encod
mirna
downregul
antigen
infect
tumor
cell
make
less
suscept
cytotox
tcell
recognit
provid
viru
way
evad
host
immun
virus
also
use
differ
method
subvert
host
mirna
purpos
liverspecif
mirna
bind
end
hepat
c
viral
genom
greatli
augment
viral
replic
inactiv
abolish
viral
replic
contrast
anoth
host
mirna
target
retroviru
primat
foami
genom
repress
viral
replic
viral
ta
protein
suppress
rnai
pathway
overcom
action
mirna
encod
within
hiv
nef
gene
regul
viral
transcript
also
document
review
trend
immunolog
vol
juli
mgkg
moreov
reduct
serum
hbv
dna
could
sustain
week
simpli
weekli
sirna
treatment
show
feasibl
use
sirna
treatment
chronic
diseas
hbv
infect
influenza
viru
iav
major
caus
respiratori
infect
worldwid
two
group
recent
use
rnai
suppress
iav
infect
mice
target
conserv
sequenc
viral
nucleoprotein
acid
polymeras
gene
tompkin
et
al
prevent
infect
multipl
isol
iav
includ
virul
avian
strain
deliveri
lung
inject
sirna
hydrodynam
intraven
inject
combin
intranas
administr
sirna
complex
transfect
reagent
oligofectamin
similarli
ge
et
al
achiev
polio
singl
mrna
use
transcrib
viral
protein
target
part
code
sequenc
result
degrad
scissor
viral
genom
rna
andor
progeni
mrna
contrast
b
virus
contain
segment
rna
genom
exampl
rotaviru
influenza
c
dna
virus
exampl
herp
simplex
papilloma
virus
mani
differ
rna
molecul
use
gener
viral
protein
necessari
target
gene
essenti
viral
life
cycl
key
viral
enzym
structur
protein
involv
cell
bind
fusion
retrovirus
eg
hiv
although
viral
protein
transcrib
either
unsplic
multipl
splice
viral
rna
gener
integr
provir
dna
genom
rna
linear
thu
target
part
genom
suppress
viral
replic
addit
viral
gene
cellular
gene
involv
viral
replic
cellular
receptor
coreceptor
eg
hiv
also
use
rnai
target
virus
abbrevi
rt
revers
transcriptas
review
trend
immunolog
juli
effici
lung
deliveri
follow
regular
intraven
inject
sirnaor
shrnaencod
dna
vector
complex
cation
polym
polyethyleneimin
pei
treatment
result
log
reduct
viral
titer
even
administ
h
postinfect
moreov
intranas
administr
shrna
vector
surfact
infasurf
r
sirna
complex
pei
also
effect
provid
intranas
approach
treat
respiratori
ill
respiratori
syncyti
viru
rsv
anoth
major
respiratori
pathogen
caus
epidem
respiratori
ill
bronchiol
pneumonia
two
studi
shown
sirna
use
effect
prophylaxi
treatment
rsv
infect
viral
nonstructur
protein
suppress
type
interferon
product
host
cell
delet
mutant
avirul
vitro
vivo
transfect
human
dendrit
cell
plasmid
encod
shrna
suppress
rsv
result
effici
induct
interferon
interferoninduc
gene
follow
rsv
infect
test
antivir
effect
vivo
vector
complex
chitosan
polymer
nanoparticl
intranas
instil
nanoparticl
harmless
mice
substanti
reduc
viral
titer
virusinduc
patholog
administ
day
infect
importantli
also
reduc
lung
inflamm
viral
titer
nearli
log
even
administ
day
infect
similar
result
also
obtain
bitko
et
al
report
author
use
synthet
sirna
target
viral
p
protein
essenti
compon
viral
rna
polymeras
administ
intranas
transit
r
transfect
reagent
sirna
substanti
suppress
viru
replic
lung
patholog
effect
also
seen
although
lesser
extent
sirna
administ
day
viral
infect
interestingli
intranas
applic
nake
sirna
without
transfect
reagent
also
effect
activ
similarli
sirna
target
p
protein
parainfluenza
viru
also
abl
suppress
viral
replic
virusinduc
patholog
epidem
caus
recent
emerg
respiratori
viral
pathogen
sar
corona
viru
scv
attract
worldwid
attent
high
degre
morbid
mortal
carri
rhesu
macaqu
monkey
model
develop
viru
intranas
instil
strain
scv
result
diseas
similar
human
diseas
li
et
al
use
system
test
sirna
potenti
therapi
scv
sirna
use
target
scv
genom
spike
protein
code
region
lipidbas
transfect
reagent
pei
transit
tko
r
use
sirna
carrier
previou
studi
might
accept
human
treatment
owe
potenti
toxic
author
studi
use
infasurf
r
dglucos
water
sirna
deliveri
infasurf
r
natur
occur
lung
surfact
protein
nontox
current
clinic
use
fold
effect
infasurf
r
deliv
sirna
lung
test
efficaci
monkey
mgkg
sirna
intranas
instil
ml
solut
treatment
substanti
reduc
clinic
symptom
lung
patholog
viral
burden
although
inhibitori
effect
maxim
sirna
administ
viral
challeng
diseas
mitig
seen
even
given
viral
challeng
thu
studi
demonstr
first
time
consider
antivir
potenti
rnai
nonhuman
primat
model
use
clinic
accept
carrier
sirna
deliveri
herp
simplex
viru
sirna
also
use
potenti
topic
microbiocid
intravagin
applic
antigreenfluorescentprotein
gfp
sirna
mix
oligofectamin
gfptransgen
mice
result
loss
gfp
express
throughout
vagina
cervix
distant
organ
liver
importantli
topic
applic
sirna
target
essenti
gene
envelop
glycoprotein
b
dnabind
protein
viral
infect
reduc
mortal
substanti
reduc
viral
shed
vagina
combin
sirna
also
effect
administ
h
infect
studi
highlight
feasibl
use
similar
approach
sexual
transmit
diseas
includ
japanes
enceph
je
west
nile
wn
virus
caus
devast
neurolog
ill
two
studi
use
rnai
suppress
virus
mous
model
bai
et
al
inject
sirna
target
viral
envelop
gene
hydrodynam
intraperiton
wnv
challeng
observ
increas
surviv
kumar
et
al
target
conserv
region
viral
envelop
gene
jev
wnv
administ
sirna
lentivir
vector
synthet
sirna
complex
cation
lipid
jetsidop
enabl
sirna
deliveri
neuron
cell
singl
intracrani
treatment
lentivir
vector
synthet
sirna
suffici
provid
almost
complet
protect
fatal
sirna
treatment
given
h
infect
also
effect
treatment
fail
later
time
point
significantli
target
sequenc
highli
conserv
jev
wnv
achiev
nearcomplet
protect
fatal
enceph
induc
either
jev
wnv
offer
possibl
use
sirna
broadspectrum
antivir
agent
suppress
relat
virus
across
speci
foot
mouth
diseas
fmd
highli
contagi
econom
devast
diseas
domest
anim
chen
et
al
use
plasmid
vector
encod
shrna
target
viral
gene
suckl
mous
model
subcutan
inject
mg
plasmid
dna
fmd
challeng
result
surviv
compar
mortal
controldnainject
mice
howev
dna
vector
inject
time
viral
challeng
increas
challeng
viru
dose
reduc
protect
consider
hiv
interest
rnai
altern
antivir
approach
particularli
strong
problem
drug
resist
toxic
cost
highli
activ
antiretrovir
therapi
haart
sever
investig
use
rnai
suppress
hiv
cell
line
primari
cell
howev
given
specif
rnai
propens
viru
mutat
pose
seriou
challeng
therapeut
use
vitro
studi
document
gener
rnaiescap
mutant
longterm
cultur
nevertheless
recent
studi
suggest
although
homolog
requir
rnai
stringent
crucial
central
residu
toler
peripher
nucleotid
chang
moreov
rnai
requir
short
stretch
homolog
possibl
target
one
region
highli
conserv
essenti
structur
function
role
sever
conserv
target
site
identifi
target
highli
conserv
vif
sequenc
lee
et
al
protect
cell
hiv
clade
includ
multipl
isol
clade
b
preval
west
host
gene
import
hiv
replic
includ
viral
receptor
coreceptor
also
target
avoid
viral
escap
synthet
lentivirallyexpress
sirna
use
prevent
hiv
entri
silenc
favor
target
base
pair
bp
delet
gene
known
harmless
confer
resist
hiv
infect
use
combin
sirna
target
conserv
viral
sequenc
host
gene
import
viral
life
cycl
might
optim
therapeut
approach
akin
antiretrovir
drug
cocktail
anoth
studi
rnai
combin
gene
therapi
approach
singl
lentivir
vector
lentiviru
engin
encod
shrna
target
revtat
mrna
short
rna
homolog
viral
transactiv
respons
region
tar
act
decoy
tat
bind
ribozym
target
host
gene
approach
might
pragmat
way
achiev
stabl
longterm
suppress
hiv
replic
therapeut
rna
target
differ
gene
product
block
hiv
replic
distinct
mechan
novel
approach
also
use
target
sirna
deliveri
infect
cell
chimer
recombin
protein
consist
singlechain
antibodi
fuse
highli
posit
charg
protamin
abl
bind
sirna
charg
interact
deliv
specif
hivinfect
c
cell
moreov
administ
bound
antitumor
sirna
specif
target
clear
experiment
tumor
mice
anoth
approach
gener
hivresist
progeni
cell
macrophag
transduc
hematopoiet
stem
cell
hsc
feasibl
approach
shown
sever
combin
immunodefici
scid
mousehuman
chimer
model
transplant
human
c
hematopoiet
stem
cell
transduc
lentiviru
express
antihiv
shrna
rnai
alreadi
enter
phase
clinic
trial
macular
degener
rsv
infect
howev
sever
hurdl
must
overcom
routin
therapeut
use
signific
limit
use
viral
infect
natur
sequenc
differ
exist
amongst
variou
serotyp
strain
within
given
viral
speci
sequenc
diverg
also
occur
accumul
mutat
viral
replic
activ
gener
escap
mutant
select
conserv
sequenc
viru
avers
mutat
use
combin
sever
viral
feasibl
cellular
target
could
overcom
limit
even
target
sequenc
base
data
avail
sequenc
virus
might
ensur
effect
field
strain
viru
thu
test
multipl
field
isol
vivo
might
necessari
although
substanti
progress
made
studi
requir
achiev
effect
nontox
deliveri
sirna
shrna
vivo
toxic
problem
vivo
use
particularli
carrier
transfect
reagent
use
deliveri
exampl
although
pei
use
one
studi
mice
sever
report
suggest
induc
toxic
effect
might
result
death
anim
thu
greater
emphasi
given
develop
clinic
accept
carrier
system
deliveri
encas
sirna
within
nontox
nanoparticl
liposom
might
enhanc
stabil
simultan
avoid
toxic
combin
target
deliveri
approach
use
antibodi
receptor
ligand
introduct
chemic
modif
sirna
encas
sirna
within
nanoparticl
liposom
could
ideal
way
improv
system
deliveri
reduc
sirna
requir
deliveri
brain
still
challeng
bloodbrain
barrier
howev
recent
studi
use
transferrin
receptor
antibodyco
immunoliposom
overcom
barrier
anoth
issu
induct
interferon
associ
inflammatori
effect
fact
tolllik
receptor
tlr
recognit
rna
plasmacytoid
dendrit
cell
seem
major
mechan
interferon
induct
administr
nake
sirna
might
induc
interferon
howev
certain
motif
within
rna
seem
crucial
interferon
induct
avoid
motif
encapsul
sirna
within
nanoparticl
could
reduc
risk
better
understand
immunostimulatori
motif
within
rna
need
tlr
activ
might
help
avoid
nonspecif
immun
activ
howev
viral
infect
induc
interferon
inflamm
might
major
limit
antivir
therapi
inadvert
target
host
gene
observ
vitro
studi
anoth
issu
need
morethorough
investig
although
grossli
observ
side
effect
report
vivo
offtarget
effect
might
necessarili
manifest
symptom
anim
could
unaccept
human
therapi
also
rnai
machineri
use
mammalian
cell
regul
cellular
gene
express
microrna
mirna
effect
exogen
introduc
sirna
mirna
function
review
investig
anoth
concern
effect
possibl
subvers
rnai
machineri
viral
protein
viral
encod
microrna
box
safeti
also
issu
use
shrna
deliveri
viral
vector
possibl
insert
mutagenesi
malign
transform
anoth
concern
effect
longterm
sirna
induct
unknown
induc
system
control
express
sirna
plasmid
viral
vector
could
offer
hope
regard
rnai
tremend
therapeut
potenti
viral
infect
major
hurdl
deliveri
appropri
cell
necessari
vivo
use
therapeut
agent
rapidli
overcom
sirna
therapi
alreadi
test
clinic
trial
futur
studi
undoubtedli
focu
refin
vivo
deliveri
method
minim
offtarget
effect
emerg
escap
mutant
vivo
optim
sirna
design
deliveri
method
deliveri
schedul
achiev
sustain
sirna
level
target
cell
emphas
investig
advanc
understand
endogen
rnai
mechan
next
year
prove
excit
time
discov
whether
rnai
becom
viabl
approach
treat
viral
infect
human
particularli
appear
clinic
symptom
